RecruitingPhase 2

To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

South Korea160 participantsStarted 2024-12-12

Plain-language summary

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

Who can participate

Age range19 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of T2DM with HbA1c between 7.0% and 10.0% (inclusive) while on diet and exercise alone for at least 8 weeks prior to screening. Exclusion Criteria: * Type 1 diabetes or another immune-mediated diabetes syndrome * BMI: \> 40 kg/m2 * C-peptide: \< 0.5ng/mL

What they're measuring

change in HbA1c at weeks 12 from baseline

Timeframe: at weeks 12 from baseline

Trial details

NCT IDNCT06647550

SponsorHyundai Pharm

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-03-31

Contact for this trial

Sin Gon Kim Korea University Anam Hospital, PhD

+82 1577-0083 k50367@korea.ac.kr

View on ClinicalTrials.gov More Type 2 Diabetes Mellitus (T2DM) trials